

38. (New) The method of claim 37 wherein the reoviruses are at least two different types of reovirus.

39. (New) The method of claim 37 wherein the reoviruses are at least two different strains of reovirus.

40. (New) The method of claim 39 wherein the different strains of reovirus are from at least two different species of animal.

41. (New) The method of claim 40 wherein at least one reoviruses is a human reovirus.

C¹
42. (New) The method of claim 40 wherein at least one reoviruses is a non-human reovirus.

43. (New) The method of claim 36 wherein at least one reovirus is administered by a route selected from the group consisting of intravascular, intrathecal, intravenous, intramuscular, subcutaneous, intraperitoneal, topical, oral, rectal, vaginal, and nasal.

44. (New) The method of claim 36 wherein at least one reovirus is delivered directly to the proliferating cells of said animal.

45. (New) The method of claim 37 wherein at least one first reovirus is administered by a route selected from the group consisting of intravascular, intrathecal, intravenous, intramuscular, subcutaneous, intraperitoneal, topical, oral, rectal, vaginal, and nasal, and at least one second reovirus is delivered directly to the proliferating cells of said animal.

46. (New) The method of claim 36 wherein at least one reovirus is administered:

- a) by a route selected from the group consisting of intravascular, intrathecal, intravenous, intramuscular, subcutaneous, intraperitoneal, topical, oral, rectal, vaginal, and nasal; and

b) delivered directly to the proliferating cells of said animal.

47. (New) The method of claim 45 wherein at least one first reovirus and at least one second reovirus are administered essentially simultaneously.

48. (New) The method of claim 45 wherein at least one first reovirus and at least one second reovirus are administered at different times.

49. (New) The method of claim 46 wherein at least one reovirus is administered as in (a) and (b) essentially simultaneously.

C 50. (New) The method of claim 46 wherein at least one reovirus is administered as in (a) and (b) at different times.

51. (New) The method of claim 36 wherein the ras-mediated proliferative disorder is a neoplasm.

52. (New) The method of claim 51 wherein the neoplasm is a glioblastoma.

53. (New) The method of claim 51 wherein the neoplasm is selected from the group consisting of a hematopoietic cancer, lung cancer, prostate cancer, colorectal cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer, pancreatic cancer, breast cancer and central and peripheral nervous system cancer.

54. (New) The method of claim 51 wherein the neoplasm is a solid neoplasm.

55. (New) The method of claim 51 wherein the neoplasm is a leukemia.

56. (New) The method of claim 51 wherein the neoplasm is metastatic.

57. (New) The method of claim 36 wherein at least one reovirus is treated with a protease prior to administration to said animal.

58. (New) The method of claim 45 wherein at least one first reovirus and at least one second reovirus are different types of reovirus.

59. (New) The method of claim 45 wherein at least one first reovirus and at least one second reovirus are different strains of reovirus.

60. (New) The method of claim 45 wherein the different strains of reovirus are from at least two different species of animal. --
